Supplementary Fig.S3 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers
Key Points
Key points are not available for this paper at this time.
Abstract
Comparison of the structure of 9MW2821 and enfortumab vedotin.
Demander à l'IA
Like
Bookmark
Share
Demander à l'IA
Like
Bookmark
Share
Supplementary Fig.S3 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers | Synapse